FDA Adverse Event and Google Trends Data Link Tirzepatide to Rare Eye Condition | Research

The takeaway

FAERS pharmacovigilance data and Google Trends analysis reveal a potential signal linking tirzepatide to nonarteritic anterior ischemic optic neuropathy (NAION).

FAERS + Google signal
Potential tirzepatide-NAION association detected through dual data source analysis

What the researchers found

FAERS analysis and Google Trends data reveal a potential safety signal linking tirzepatide to NAION, warranting further pharmacovigilance and clinical investigation.

Why it matters

NAION can cause permanent vision loss. As tirzepatide prescriptions grow rapidly, even rare eye complications affect thousands of patients.

How the study worked

Pharmacovigilance analysis of FAERS adverse event reports combined with Google Trends analysis for NAION-related search patterns associated with tirzepatide use.

What this study cannot tell us

FAERS reports are voluntary and subject to reporting bias. Google Trends correlations cannot establish causation. NAION has many risk factors independent of medication use.

How to read the evidence

Pharmacovigilance signal detection — identifies a potential risk but cannot confirm causation. Lowest tier of safety evidence.

When this study was published

Published in 2026; addresses emerging safety concerns with widely prescribed drug.

The bigger picture

This reflects the growing importance of digital pharmacovigilance — using adverse event databases and internet search patterns to detect drug safety signals in real time.

Questions still open

Is the NAION risk specific to tirzepatide or shared across all GLP-1/GIP drugs?
Does rapid weight loss itself contribute to NAION risk?

Common questions

Can tirzepatide affect my vision?

A potential safety signal links tirzepatide to NAION, a rare condition causing sudden painless vision loss. This is very rare, but report any sudden vision changes to your doctor immediately.

What is FAERS?

The FDA Adverse Event Reporting System (FAERS) collects reports of side effects from medications. Researchers analyze these reports to detect potential safety signals that clinical trials may not have caught.

Read the original research

Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.

Hospital pharmacy, 00185787251403040

View on PubMed ↗Publisher’s paper ↗

Citation

Castellana, Eleonora; Chiappetta, Maria Rachele. (2026). Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.. Hospital pharmacy, 00185787251403040. https://doi.org/10.1177/00185787251403040